chloroquine has been researched along with Lewy Body Disease in 1 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Lewy Body Disease: A neurodegenerative disease characterized by dementia, mild parkinsonism, and fluctuations in attention and alertness. The neuropsychiatric manifestations tend to precede the onset of bradykinesia, MUSCLE RIGIDITY, and other extrapyramidal signs. DELUSIONS and visual HALLUCINATIONS are relatively frequent in this condition. Histologic examination reveals LEWY BODIES in the CEREBRAL CORTEX and BRAIN STEM. SENILE PLAQUES and other pathologic features characteristic of ALZHEIMER DISEASE may also be present. (From Neurology 1997;48:376-380; Neurology 1996;47:1113-1124)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The autophagy-lysosome pathway (ALP) regulates intracellular homeostasis of the cytosolic protein SNCA/alpha-synuclein and is impaired in synucleinopathies, including Parkinson disease and dementia with Lewy bodies (DLB)." | 3.88 | Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype. ( Adame, A; Barkovits, K; Bergmann, A; Buzás, EI; Emmanouilidou, E; Galasko, D; Kittel, A; Klucken, J; Lie, DC; Marcus, K; Marxreiter, F; Masliah, E; Menges, S; Minakaki, G; Mollenhauer, B; Rockenstein, E; Schaeffner, I; Schlötzer-Schrehardt, U; Vekrellis, K; Winkler, J; Xiang, W, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Minakaki, G | 1 |
| Menges, S | 1 |
| Kittel, A | 1 |
| Emmanouilidou, E | 1 |
| Schaeffner, I | 1 |
| Barkovits, K | 1 |
| Bergmann, A | 1 |
| Rockenstein, E | 1 |
| Adame, A | 1 |
| Marxreiter, F | 1 |
| Mollenhauer, B | 1 |
| Galasko, D | 1 |
| Buzás, EI | 1 |
| Schlötzer-Schrehardt, U | 1 |
| Marcus, K | 1 |
| Xiang, W | 1 |
| Lie, DC | 1 |
| Vekrellis, K | 1 |
| Masliah, E | 1 |
| Winkler, J | 1 |
| Klucken, J | 1 |
1 other study available for chloroquine and Lewy Body Disease
| Article | Year |
|---|---|
Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype.
Topics: alpha-Synuclein; Animals; Autophagosomes; Autophagy; Biomarkers; Cells, Cultured; Chloroquine; Exoso | 2018 |